Collecting Duct Carcinoma
NCI Definition: Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor. 
Collecting duct carcinomas most frequently harbor alterations in NF2, CDKN2A, FBXW7, CDKN2B, and SMARCB1 .
NF2fs, FBXW7 Mutation, CDKN2B Loss, CDKN2A Loss, and SETD2 Mutation are the most common alterations in collecting duct carcinoma .
There are 2 clinical trials for collecting duct carcinoma, of which 1 is open and 1 is completed or closed. Of the trials that contain collecting duct carcinoma as an inclusion criterion, 2 are phase 2 (1 open).
Bevacizumab, cabozantinib, and gemcitabine are the most common interventions in collecting duct carcinoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.